Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors
Table 3
Prevalence of diabetes and hypertension according to demographics, HIV-related, and biological characteristics of the study population.
Characteristics
Diabetes
Hypertension
Frequency (%)
P
Frequency (%)
P
ART duration, months
<0.001
0.81
Short
8.3
27.4
Long*
32.8
28.8
Age, years
<0.001
0.002
<45
5.1
17.3
≥45
20.8
35.4
Sex
0.41
0.12
Male
16.7
33.3
Female
12.9
24.3
BMI, kg/m²
0.64
0.22
<25
13.8
25.9
≥25
16.2
33.8
BMI at treatment initiation, kg/m²
0.22
0.35
<25
13.4
27.2
≥25
24.0
36.0
CDC stage
0.63
0.53
A
12.5
18.7
B
12.1
26.3
C
16.5
30.7
HCV or HBV coinfection
0.47
0.39
Yes
11.1
33.3
No
15.2
26.9
CD4 cell count, cells/μL
0.70
0.09
≤200
7.7
7.7
>200
14.8
29.3
CD4 cell count at treatment initiation, cells/μL
0.47
≤200
15.9
>200
12.5
HIV viral load copies/mL
0.64
0.56
<50
14.9
28.9
≥50
12.2
24.4
Total cholesterol (g/L)
0.03
0.11
<1.5
12.9
26.8
≥1.5
33.3
44.4
Triglycerides (g/L)
0.01
0.53
<2.4
13.0
27.7
≥2.4
45.4
36.4
*Long duration of ART was defined for durations ≥119 months for comparison of diabetes prevalence and for durations ≥107 months for the comparison of hypertension.
